Table 1 Baseline clinical, demographic, biochemical and angiographic features of patients in different SYNTAX score (SS) groups
Variables | Total (N = 332) | SS ≤ 12 (n = 114) | 12 < SS ≤ 21.5 (n = 113) | SS > 21.5 (n = 105) | P-value |
|---|---|---|---|---|---|
Age (years) | 39.30 (4.50) | 39.30 (4.70) | 39.60 (4.70) | 39.10 (3.90) | 0.57 |
Body mass index, kg/m2 | 25.00 (2.51) | 25.28 (2.70) | 24.64 (2.30) | 25.06 (2.51) | 0.46 |
SBP, mmHg | 132.50 (23.20) | 132.80 (21.40) | 133.20 (24.30) | 131.30 (24.20) | 0.96 |
DBP, mmHg | 81.0 (14.7) | 80.2 (14.5) | 84.1 (15.1) | 78.5 (14.2) | 0.07 |
Past history | |||||
 Hypertension | 148 (44.60) | 44 (39.00) | 49 (43.40) | 55 (52.10) | 0.26 |
 Diabetes | 46 (13.80) | 8 (7.00) | 12 (10.60) | 27 (25.70) | < 0.01* |
 Familial hypercholesterolemia | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
 Familial PCAD | 34 (10.30) | 16 (14.00) | 9 (8.00) | 9 (8.60) | 0.36 |
 Smoking | 256 (77.10) | 89 (78.10) | 83 (73.50) | 84 (80.00) | 0.63 |
MI type | |||||
 STEMI | 289 (87.10) | 95 (83.30) | 96 (85.00) | 98 (93.30) | 0.18 |
 NSTEMI | 43 (12.90) | 19 (16.70) | 17 (15.00) | 7 (6.70) |  |
Biochemistry | |||||
 White blood cells, 109/L | 11.45 (3.12) | 11.23 (3.29) | 11.20 (2.56) | 11.95 (3.46) | 0.21 |
 Urea, mmol/L | 4.69 (1.64) | 4.48 (2.34) | 4.55 (1.70) | 5.05 (1.89) | 0.05 |
 Lp(a), nmol/L | 21.15 (51.38) | 19.00 (33.65) | 18.05 (51.58) | 24.95 (53.63) | 0.28 |
 TC, mmol/L | 5.01 (1.12) | 4.84 (0.98) | 4.98 (1.19) | 5.22 (1.16) | 0.11 |
 LDL-C, mmol/L | 3.35 (1.04) | 3.18 (0.92) | 3.26 (0.98) | 3.63 (1.17) | 0.02* |
 VLDL-C, mmol/L | 0.49 (0.48) | 0.55 (0.53) | 0.48 (0.48) | 0.49 (0.43) | 0.87 |
 HDL-C, mmol/L | 0.96 (0.31) | 0.98 (0.42) | 0.92 (0.25) | 0.97 (0.20) | 0.25 |
 Triglycerides, mmol/L | 2.11 (1.49) | 2.12 (1.35) | 2.11 (1.53) | 2.09 (1.42) | 0.99 |
 Apob, g/L | 1.20 (0.30) | 1.15 (0.27) | 1.17 (0.29) | 1.29 (0.32) | < 0.01* |
 ALT, U/L | 54.10 (41.55) | 48.75 (47.45) | 55.55 (39.98) | 54.5 (41.78) | 0.97 |
 Glucose, mmol/L | 5.62 (2.93) | 5.52 (1.88) | 5.51 (2.35) | 6.52 (4.06) | 0.04* |
 Creatinine, μmol/L | 79.54 (19.74) | 77.56 (12.30) | 76.96 (16.82) | 84.44 (27.16) | 0.09 |
Coronary heart disease | |||||
 LVEF, % | 49.80 (7.70) | 51.30 (7.10) | 50.40 (7.80) | 47.60 (7.70) | < 0.01* |
 Creatine kinase, U/L | 1649.50 (2451.00) | 1324.00 (1903.00) | 1744.00 (2332.80) | 1950.00 (2674.00) | 0.18 |
 CK-MB, U/L | 125.5 (189.8) | 111.5 (184.0) | 121.0 (174.0) | 162.0 (249.0) | 0.33 |
 c-Tnt, ng/mL | 3.57 (5.14) | 2.61 (5.38) | 3.47 (4.62) | 4.01 (5.14) | 0.15 |
 hs-Crp, mg/L | 6.18 (13.01) | 6.70 (15.04) | 5.55 (11.68) | 5.92 (13.06) | 0.88 |
 NT-proBnp, pg/mL | 446.0 (832.4) | 407.6 (809.8) | 437.5 (789.5) | 528.1 (905.2) | 0.29 |
Prior drug use | |||||
 Statin | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
 Ezetimibe | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – |
 Beta-blocker | 44 (13.30) | 16 (14.00) | 14 (12.40) | 14 (13.30) | 0.22 |
 CCB | 34 (10.20) | 11 (9.70) | 14 (12.40) | 9 (8.60) | 0.45 |
 ARB/ACEI | 32 (9.70) | 9 (7.90) | 11 (9.70) | 12 (11.40) | 0.31 |
Biomarker | |||||
 Pcsk9, ng/mL | 175.66 (92.9) | 160.72 (71.39) | 170.21 (112.64) | 197.95 (87.38) | < 0.01* |